{
  "docId": "019de075-4aec-72cf-a6e0-519f4b0af11c",
  "docSlug": "80e6ab6db3df4d91b63f99a2a4cf6dc3",
  "documentTitle": "Exscientia | Investor Presentation Deck | 73 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 46,
  "pageCount": 73,
  "prevPage": 45,
  "nextPage": 47,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "TPP stands for Target Product Profile.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-4aec-72cf-a6e0-519f4b0af11c/46",
  "deckHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c",
  "deckJsonHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c.json",
  "deckAnchorHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c#slide-46",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.07,
        "y": 0.65
      },
      "kind": "chart",
      "text": "Better Efficacy at Approximately Half the Dose",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8bb0063-1f1e-4bfc-adc4-83484312aa47",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.65,
        "y": 0.28
      },
      "kind": "image",
      "text": "Target graphic",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6040422-b5b5-4234-8e7f-36c3ee4582d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.35,
        "x": 0.6,
        "y": 0.53
      },
      "kind": "list",
      "text": "Key Elements of TPP: 24h coverage of IC80, Predicted human dose <200mg/day, High demands on target potency, selectivity, pharmacokinetics, Robust translation into cellular and human whole blood assays",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2807511-bffa-46ef-91f7-ff1fb55e2ad8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.07,
        "y": 0.33
      },
      "kind": "list",
      "text": "High-value immunology target that had eluded many large biopharmas due to selectivity challenges. Balanced profile provided improvements in human whole blood potency and predicted human dose <200mg/day. Excellent selectivity.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe841e91-41c9-4d67-9e64-3e03d5a66f74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Expert led AI-design to deliver against a high-value target",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6786192-aac5-4eeb-830c-13bd26c24cae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "PKC-theta: In-licensed by BMS in August 2021",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5539d08-a83d-4a85-a14b-6a436c0b95a0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "51ae8ec9-ec21-4ea7-b941-145b99bbfb29",
      "evidence": "list/bullet: High-value immunology target that had eluded many large biopharmas due to selectivity challenges. Balanced profile provided improvements in human whole blood potency and predicted human dose <200mg/day.",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 73,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "02ebf716-8af1-4eca-8937-1321b5d2471c",
      "evidence": "The deck presents the consequences of not adopting Exscientia's technology throughout the presentation",
      "position": 0,
      "objective": "What is the cost of not adopting Exscientia's AI-driven precision medicine platform?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 72,
      "from": 29,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "c1ff2e13-046f-4a68-9f90-d544bd3e6de9",
      "evidence": "The deck presents information on Exscientia's clinical stage compounds and their potential benefits",
      "position": 1,
      "objective": "What are the potential benefits of Exscientia's clinical stage compounds?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}